Decision Resources, one of the world's leading research and advisory
firms for pharmaceutical and healthcare issues, finds that the malignant
melanoma drug market, driven by the launch of emerging agents, will
experience robust annual 12 percent growth through 2012 in the United States,
France, Germany, Italy, Spain, the United Kingdom and Japan.
The new Pharmacor report entitled Malignant Melanoma finds that the
launch of Bristol-Myers Squibb/Medarex's ipilimumab will significantly
increase the size of the malignant melanoma drug market as sales of
ipilimumab will grow at an annual rate of 17 percent from 2012 through 2017.
Ipilimumab will account for nearly a quarter of malignant melanoma drug sales
in 2012 and just over a third of sales in 2017.
The report also finds that, as a result of recently published data on
vaccines in malignant melanoma, interviewed experts lack confidence in the
vaccine drug class. Among cancer vaccines that had been previously regarded
as promising emerging agents, Progenics' GM2-KLH21 has recently shown to be
detrimental in early stage malignant melanoma.
"The incidence of malignant melanoma is rising rapidly," said Marcus
Hoyle, analyst at Decision Resources. "A huge unmet need in the treatment of
this cancer remains for the development of therapies that can prolong overall
survival in the advanced stages as prognosis at this stage is poor with a
median overall survival of six to nine months."
About Decision Resources
Decision Resources is a world leader in
market research publications, advisory services and consulting designed to
help clients shape strategy, allocate resources and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.
Decision Resources
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of
the healthcare industry. Clients rely on this analysis and data to make
informed decisions. Please visit Decision Resources, Inc. at
DecisionResourcesInc.
Decision Resources, Inc.